Labcorp raised its full‑year revenue growth outlook to a range of 5.4%‑6.3%, adding 30 basis points at the midpoint, and lifted the adjusted EPS range to $18.10‑$18.55, up $0.30 at the midpoint. The higher guidance and expanded buyback capacity signal stronger cash flow and earnings potential, making the stock more attractive to growth‑focused investors.
Key Highlights
- Revenue $3.73 billion up 5.8% · Next catalyst: Q3 earnings release
- Quarterly dividend remains unchanged
- Share repurchase authorization increased by $1.0 billion, expanding the program
- Adjusted EPS rose to $4.99, a 14.9% increase year‑over‑year
The company also kept its quarterly dividend steady. Shares have shown price appreciation consistent with market trends, reflecting investor optimism about the upgraded forecasts.
Revenue Guidance Lift
The new guidance reflects a 5.8% jump in second‑quarter revenue to $3.73 billion from $3.53 billion a year earlier. Organic growth contributed modestly while acquisitions added further strength, with foreign exchange effects modest. The uplift positions Labcorp ahead of many peers and suggests the firm can sustain momentum despite a competitive environment.
By extending the top‑line outlook, the company signals confidence in its specialty testing and oncology pipelines, which could translate into higher market share. The increase also narrows the gap between analyst expectations and management targets, tightening valuation spreads.
Earnings Outlook Expansion
Adjusted earnings per share climbed to $4.99, a 14.9% rise from $4.35, underscoring margin improvement alongside revenue growth. Operating income increased substantially, and adjusted operating income rose, boosting the adjusted operating margin. These improvements are driven by higher pricing power in diagnostics and efficiency gains in the biopharma laboratory services segment.
The stronger earnings base supports the revised adjusted EPS range of $18.10‑$18.55 for the full year, reinforcing the company's capacity to generate cash for shareholders.
Capital Allocation Moves
Labcorp announced a $1.0 billion increase in its share repurchase authorization, expanding the program. In the quarter, the company executed a significant share buyback program and maintained dividend payments, while deploying capital toward strategic acquisitions. It also retired a portion of senior notes, reducing overall leverage.
These actions improve earnings per share through buyback dilution mitigation and signal a disciplined return‑of‑capital strategy, which may appeal to income‑oriented investors. The combined effect of higher guidance and strong capital returns could compress the price‑to‑earnings multiple.
Near‑Term Catalyst
The next catalyst arrives with the upcoming third‑quarter earnings release, when the company will detail performance in its expanding oncology portfolio and report on the rollout of the new Marker by Labcorp™ genetic health panel. That filing will test whether the upgraded guidance translates into actual results and may prompt further share price movement.
Peers Moving on This News
- CVS Health Corp (CVS) little changed
- Cigna Group (CI) little changed
- Quest Diagnostics Inc (DGX) little changed
Analysis based on the Form 8-K filed 30 July 2026.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...